Hims, Super Bowl and Hers

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...